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Abstract
Background and aims—Some patients with eosinophilic esophagitis (EoE) have an extremely 
narrowed esophagus, but the characteristics of this group have not been extensively described. We 
aimed to characterize the narrow-caliber phenotype of EoE, determine associated risk factors, and 
identify differences in treatment response in this sub-group of patients.
Methods—This retrospective cohort study from 2001 to 2014 included subjects with a new 
diagnosis of EoE per consensus guidelines. Demographic, endoscopic, histologic, and treatment 
response data were extracted from medical records. An “extreme narrow-caliber esophagus” was 
defined when the neonatal endoscope was required to traverse the esophagus due to inability to 
pass an adult endoscope. Cases with and without the extreme narrow-caliber esophagus were 
compared. Multivariable logistical regression was performed to assess treatment outcomes.
Results—Of 513 patients with EoE, 46 (9%) had an extreme narrow-caliber esophagus. These 
cases were older (33 vs 22 years; p<0.01), had longer symptom duration (11 vs 3 years; p<0.01), 
more dysphagia (98% vs 66%; p<0.01), and food impactions (53% vs 31%; p<0.01). Dilation was 
more common with extreme narrowing (69% vs 17%; p<0.01). Narrow-caliber patients were more 
refractory to steroid treatment, with lower symptom (56% vs 85%), endoscopic (52% vs 76%), 
and histologic (33% vs 63%) responses (p<0.01 for all), and these differences persisted after 
multivariate analysis.
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Conclusion—The extreme narrow-caliber esophagus is a more treatment-resistant sub-
phenotype of EoE and is characterized by longer symptom duration and requirement for multiple 
dilations. Recognition at diagnosis of EoE can provide important prognostic information.
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Introduction
Eosinophilic esophagitis (EoE) is a chronic antigen-mediated disease characterized by a 
dense eosinophilic infiltrate and esophageal dysfunction [1]. With the increasing prevalence 
of EoE over the past decade, there has been a greater understanding of the variability in 
disease manifestation [2-6]. It is well established that adults and children have different 
clinical presentations [7-9]. Children commonly present with difficulty feeding, vomiting, 
heartburn, and abdominal pain, whereas adults typically have symptoms of dysphagia, 
strictures, and food impactions [10-13]. It is unknown whether these symptomatic 
differences represent distinct phenotypes of EoE or a progressive disease course that evolves 
from an inflammatory to a fibrostenotic stage in a time-dependent manner [14].
Distinct clinical and endoscopic features differentiate inflammatory and fibrostenotic EoE 
phenotypes [15]. Inflammatory changes on endoscopy manifest as white exudates, linear 
furrows, and edema, and patients typically present with symptoms such as nausea and 
abdominal pain [15, 16]. Patients with fibrotic features experience dysphagia and tend to 
have rings, strictures, and crepe paper mucosa on examination [10]. In addition, 
approximately 10% of EoE patients have a diffusely stenotic esophagus described as a 
narrow-caliber or small-caliber esophagus [1]. This can be characterized as a narrowed 
esophagus with a fixed internal diameter that can either extend the entire length of the 
esophagus or skip segments [13, 17], which differs from a stricture that is focal [17]. 
Although the narrow-caliber esophagus has been recognized as a distinct manifestation of 
EoE previously, the features of this group of patients has not been described in detail. 
Currently, there is no standardized definition of a narrow-caliber esophagus, and it is 
unknown whether it represents a new sub-phenotype of EoE.
The primary aim of this study is to characterize EoE patients with a narrow-caliber 
esophagus, determine associated risk factors, and identify differences in treatment response 
to topical steroids for this sub-group. We hypothesize based on clinical experience that the 
extreme narrow-caliber esophagus is a distinct EoE sub-phenotype and is associated with 
older age, longer disease duration, and treatment resistant disease compared with patients 
with a regular-caliber esophagus.
Methods
Study Design, Study Population, and Data Source
This is a retrospective cohort study conducted at the University of North Carolina (UNC) 
using the UNC EoE clinicopathology database from 2001 to 2014. The development and 
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characteristics of the database have been previously reported [15, 18, 19]. All subjects 
included in the study were patients at UNC with an incident diagnosis of EoE who met 
consensus diagnostic guidelines [1, 20, 21], including symptoms of esophageal dysfunction, 
≥15 eosinophils per high-power field (eos/hpf) (hpf area = 0.24 mm2), non-response to a 
proton pump inhibitor trial, and exclusion of competing causes. EoE cases were categorized 
as having an extreme “narrow-caliber” esophagus if the endoscopy report documented a 
requirement to use a neonatal endoscope (<6 mm diameter) to traverse the esophagus due to 
inability to pass an adult upper endoscope secondary to narrowing (Fig. 1). Cases of EoE 
that allowed passage of an adult upper endoscope despite a decrease in esophageal luminal 
diameter are referred to as “regular-caliber” for the purposes of this study. Of note, presence 
of focal esophageal strictures could be present in either group. The study was approved by 
the University of North Carolina Institutional Review Board.
Data were abstracted from the UNC electronic medical records, endoscopy reports, and 
pathology reports. Patient demographics, symptom characteristics, and duration before 
diagnosis, history of atopic disease, and food allergy (documented by presence of allergic 
symptoms with reintroduction of a food or by testing directed by an allergist) were collected. 
Endoscopic findings obtained included presence of rings, linear furrows, white plaques or 
exudates, decreased vascularity, crêpe-paper mucosa, strictures, and therapeutic 
interventions such as dilations. For histologic data, the maximum eosinophil count (eos/hpf; 
hpf area = 0.24 mm2) [22] was used, as determined by pathologist review of biopsy samples. 
Finally, data on topical corticosteroid treatment, prescribed at the discretion of the 
gastroenterologist, were recorded. Steroid treatment at our institution consistent of an 8-
week course of budesonide (0.5-1 mg twice daily mixed into a slurry with 5 g sucralose) [23, 
24] or fluticasone (440-880 ug twice daily) [25]. Patients were treated exclusively with 
topical steroids and did not receive concomitant dietary therapy. All subjects who completed 
an 8-week course of topical steroid treatment with either budesonide or fluticasone were 
evaluated for treatment effect.
Definition of Measures
In addition to characterizing the features of the narrow-caliber esophagus, 3 outcomes were 
also extracted from medical records to assess response to an 8-week course of topical 
corticosteroid treatment. Symptom response was defined as a subjective patient report of 
global improvement of prior symptoms (such as dysphagia, food impaction, abdominal pain, 
nausea, vomiting, heartburn, chest pain, failure to thrive) characterized as yes or no. 
Endoscopic response was defined as the resolution of previously present features such as 
rings, furrows, and plaques. Finally, histologic response was defined as achieving an 
eosinophil count of <15 eos/hpf after a completed course of steroid treatment.
Statistical Analysis
Descriptive statistics were used to examine subject characteristics, and bivariate analyses 
were performed to determine the relationship between each independent variable and the 
presence of an extreme narrow-caliber esophagus, using the Student t test and Wilcoxon 
rank-sum for continuous variables and the Pearson chi-square tests for categorical variables. 
Multivariable logistic regression was used to estimate the odds of symptomatic, endoscopic, 
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and histologic response to steroid treatment in patients with an extreme narrow-caliber 
esophagus compared with regular-caliber, after adjusting for potential confounding factors. 
An additional sub-group analysis was performed to assess outcomes when comparing EoE 
cases with a narrow-caliber, to cases with a regular-caliber esophagus but with strictures. 
Based on these models, adjusted and unadjusted odds ratios and 95% confidence intervals 
were calculated. All analyses were performed using Stata 13 (College Station, Tex).
Results
Clinical Characteristics of the Narrow-Caliber Sub-Phenotype
Out of 513 subjects, 46 (9%) had an extreme narrow-caliber esophagus (Table 1). Mean age 
at diagnosis of EoE was significantly higher in the narrow-caliber group at 33 years, with 
only 13% being children less than 18 years, compared with 22 years in the regular-caliber 
subjects (p<0.01). There were no differences between the 2 groups in terms of race and sex. 
Narrow-caliber patients had longer symptom duration (11 vs 3 years, p<0.01) and higher 
rates of dysphagia (98% vs 66%) and food impaction (53% vs 31%). Both groups were 
comparable for having a history of atopic diseases, allergy, and asthma. Between 2001 and 
2014, the proportion of narrow-caliber cases diagnosed per year did not change with time.
Endoscopic and Histologic Characteristics of the Narrow-Caliber Sub-Phenotype
Endoscopic findings of rings, furrows, white plaques, and crêpe-paper mucosa were 
significantly more common in the narrow-caliber group (Table 2), and 72% had strictures 
compared with only 13% with a regular-caliber. All of the narrow-caliber subjects required 
dilation therapy at some point with a median number of 3 dilations required per patient. In 
addition, 33% (n = 15) of the narrow-caliber group who were dilated underwent repeat 
dilation within 8 weeks. In contrast, only 26% of the regular-caliber patients underwent 
dilations with a majority requiring only a single dilation. There was no difference in the 
maximum number of eos/hpf with a median of 78 and 60 eosinophils in the narrow and the 
regular patients.
Response to Steroids: Narrow-caliber versus Regular-caliber
Narrow-caliber esophagus patients had less improvement of symptoms, endoscopic findings, 
and histology after topical steroid treatment (Table 3). Only 56% reported a global 
subjective improvement in esophageal and gastrointestinal symptoms compared with 85% 
with a regular-caliber, p<0.01. Similarly, fewer in the narrow-caliber group had improvement 
of endoscopic findings characteristic of EoE (52% vs 76%, p<0.01) or histologic response 
(33% vs 63%, p<0.01), as evidenced by a higher median eosinophil count when compared 
with the regular-caliber subjects (45 vs 3 eos/hpf, p<0.01).
These findings persisted after multivariable analysis adjusting for symptom duration, history 
of dilation, and age. Those with a narrow-caliber esophagus had decreased odds of 
improvement in symptoms (OR, 0.28; 95% CI, 0.08-0.96), endoscopic findings (OR, 0.31; 
95% CI, 0.10-0.90), and histology (OR, 0.27; 95% CI, 0.09-0.74), after a course of steroids 
compared with the regular-caliber patients (Table 4).
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Response to Steroids: Narrow-caliber versus Strictures
There were 60 patients with EoE who had strictures but did not have the extreme narrow-
caliber phenotype (Table 5). When these patients were compared with the narrow group (n = 
46), there were no significant differences in terms of age at biopsy, race, atopic history, 
symptom duration, and maximum eosinophil count before treatment. As with the primary 
analysis, significantly fewer in the narrow-caliber group had symptomatic (56% vs 89%), 
endoscopic (52% vs 88%), and histologic (33% vs 68%) response to steroids with a higher 
maximum eosinophil count (median eos/hpf (IQR): 45 (3-90) versus 2 (0-16)) after steroids, 
compared with those with strictures but a normal-caliber esophagus (p<0.01 for all) (Table 
6). These findings also persisted on multivariable analysis with the narrow-caliber esophagus 
subjects having decreased odds of symptom (OR, 0.16; 95% CI, 0.04-0.67), endoscopic 
(OR, 0.14; 95% CI, 0.04-0.55), and histologic (OR, 0.24; 95% CI, 0.08-0.71) improvement 
compared with the stricture group.
The effect of steroid type and dose on histologic response was assessed when comparing the 
narrow-caliber group to those with strictures and to the regular-caliber patients. No 
differences in histologic response or mean number of eosinophils after treatment were noted 
based on steroid type or dose in all 3 groups (data not shown).
Discussion
In this study, we aimed to further characterize a possible new sub-phenotype of EoE, the 
extreme narrow-caliber esophagus. Narrow-caliber patients were predominantly adults with 
longer symptom duration and delayed diagnosis, with frequent symptoms of dysphagia, high 
rates of food impaction, and a universal requirement for esophageal dilation. Importantly, 
patients in the narrow-caliber group were treatment resistant to topical steroids, with 
profoundly decreased odds of having symptomatic, endoscopic, and histologic response to 
treatment when compared with EoE patients with a regular-caliber esophagus. Moreover, 
these clinical outcomes appeared to be specific to the narrow-caliber group, and were not 
seen in EoE cases with a regular-caliber esophagus and focal strictures, though the groups 
had similar clinical and histologic characteristics. Due to these differences in 
clinicopathological presentation and non-response to steroid treatment, identifying the sub-
group of EoE patients with a narrow-caliber esophagus can have important prognostic 
implications.
Although the inflammatory and fibrostenotic phenotypes of EoE have been previously 
described [14, 15], there is limited literature on the narrow-caliber esophagus. One of the 
earliest studies demonstrated that the narrow-caliber was a common finding in young 
patients with dysphagia, which was difficult to detect, and was characterized by the presence 
of long rents after dilation [26]. Since then, the reported prevalence of narrow-caliber in EoE 
has ranged from 5% to 28% based on endoscopy with larger studies documenting 9% to 
10%, which is comparable with the prevalence in our data [1, 13, 27-30]. It is plausible that 
the prevalence is even higher as a recent study highlighted that the narrow-caliber may be 
missed on endoscopy [31]. Endoscopically, the narrow-caliber esophagus has been described 
as a diffuse decrease in the caliber of the thoracic esophagus [32], and on barium 
esophagram as narrowing with a mean length of >15 cm and diameter <20 mm [32, 33]. 
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Despite the recognition of the narrow-caliber as an endoscopic and radiographic sign of 
EoE, there have been no studies to date to our knowledge that have characterized it as a 
distinct sub-phenotype of EoE.
In our study, the clinical and endoscopic features of the narrow-caliber esophagus are 
consistent with sequelae of esophageal remodeling and fibrostenosis. Driven by a chronic 
inflammatory process, esophageal remodeling involves basal cell hyperplasia, subepithelial 
and transmural fibrosis, and smooth muscle hypertrophy [34-40], which leads to a decrease 
in esophageal luminal diameter and compliance [41]. Therefore, the pathogenesis of EoE 
may be an evolution from an inflammatory to a fibrostenotic state [10, 15], as evidenced by 
the low prevalence of strictures in children and a high prevalence of strictures or esophageal 
narrowing in those with longer symptom duration before diagnosis [14, 15, 42, 43]. In 
addition, EoE patients with strictures or a narrow-caliber have lower esophageal 
distensibility [44]. This raises the question of whether the narrow-caliber esophagus 
represents a more severe and end-stage manifestation or a treatment-resistant variant of the 
fibrostenotic phenotype. Although findings such as the increased prevalence of narrow-
caliber in adults, longer symptom duration, fibrosis and lower esophageal distensibility 
suggest an end-stage fibrostenotic state, the decreased response to steroids compared with 
the regular-caliber cases and those with focal strictures is a new finding, and argues that it is 
likely a separate sub-phenotype. Reasons for the poor steroid response, which was not 
explained by steroid dose or type, remain unclear and need to be further elucidated.
Recognizing disease phenotypes that are treatment resistant is important for prognostic 
implications. There is some evidence that patients with strictures do not respond as 
effectively to steroids when compared with those with inflammatory symptoms [19, 45-47]. 
Because patients with a narrow-caliber sub-phenotype have even lower odds of 
symptomatic, endoscopic, and histologic improvement with topical steroids, these patients 
may benefit more from sequential dilation therapy, particularly from the symptom response 
standpoint. However, more aggressive dilation therapy would not result in an improvement 
of the poor histologic response noted in the narrow-caliber group. Therefore, it is possible 
that the narrow-caliber group may require higher doses of steroids, longer duration of 
steroids, or primary dietary therapy, but this requires further study.
The interpretation and generalizability of our study results are limited by its retrospective 
single-center design. Because of this, patients' symptom response could only be reported as 
a subjective dichotomous variable of yes or no, and validated symptom scores were not used. 
Similarly, different endoscopists performed the procedures and a formalized endoscopic 
scoring system [48] could not be used resulting in minor differences in reporting of 
endoscopic findings. However, we do not anticipate that this affected the results in a 
significant manner because the same parameters were used across both comparison groups, 
but we acknowledge that future prospective studies should be conducted to confirm our 
response data possibly using standardized endoscopic criteria and documentation of 
esophageal luminal diameter. We acknowledge that there was no formal assessment of the 
luminal diameter in defining the narrow-caliber cases other than the use of a neonatal 
endoscope at the endoscopist discretion. Due to this, there may have been misclassification 
of some stricture cases as narrow-caliber esophagus. In order to address this, we compared 
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groups with strictures to the narrow-caliber cases and found a significantly decreased 
treatment response that persisted in the narrow-caliber group. Therefore, any 
misclassification of stricture cases as narrow-caliber would have biased our results towards 
the null hypothesis. Finally, because the patients in this study were treated with topical 
steroids, we were not able to comment about treatment response with dietary elimination.
Our study has important strengths as well. To our knowledge, this is the first study to 
characterize the extreme narrow-caliber esophagus in detail and this was possible due to our 
large sample size. Second, our study is also the first to demonstrate that the narrow-caliber 
group is more treatment resistant to steroids and this can have significant clinical 
implications. Third, the data extraction protocol was standardized and extensive, and our 
analysis allowed stratification by presence of stricture, to show that the narrow-caliber cases 
had worse treatment response than focal stricture cases, arguing that it is likely a different 
EoE sub-phenotype rather than end-stage fibrostenotic disease.
In summary, we characterized a new sub-phenotype of EoE, the extreme narrow-caliber 
esophagus defined by the need to use a neonatal endoscope to traverse the esophagus due to 
inability to pass an adult endoscope secondary to severe narrowing. Narrow-caliber occurs 
primarily in adults with longer symptom duration and shares many of the fibrostenotic 
features, but is more treatment resistant to steroids with poor symptomatic, endoscopic, and 
histologic response when compared with non-narrowed EoE patients or those with strictures. 
Therefore, it may be a group that needs more aggressive dilation, higher doses of steroids, or 
other therapies. Recognizing this group of EoE patients can be helpful in driving treatment 
decisions and predicting treatment response.
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Figure 1. 
These images demonstrate the endoscopic appearance of the extreme narrow-caliber 
esophagus characterized by significant narrowing of the luminal diameter. All 3 images 
show the presence of esophageal rings and edema and also white plaques/exudates in the 
third image.
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Table 1
Demographic and clinical characteristics of patients with extreme narrow-caliber and 
regular-caliber esophagus
Narrow-calibera (n = 46) Regular-caliber (n = 467) P valueb
Age at biopsy (mean years, SD) 33.4 (13.1) 22.1 (19.2) <0.01
 Children <18 years (n, %) 6 (13.0) 216 (46.3) <0.01
Male (n, %) 32 (70) 332 (71) 0.83
Whites (n, %) 42 (93) 373 (81) 0.40
Symptoms (n, %)
Dysphagia 45 (98) 302 (66) <0.01
Food impaction 24 (53) 138 (31) <0.01
Chest pain 5 (11) 46 (10) 0.88
Heartburn 11 (24) 179 (40) 0.04
Abdominal pain 2 (4) 106 (24) <0.01
Nausea 1 (2) 57 (13) 0.04
Vomiting 7 (16) 124 (28) 0.07
Failure to thrive 1 (2) 57 (13) 0.04
Symptom length before diagnosis (median years, IQR) 11.0 (5-15) 3.4 (1-9) <0.01
Atopic diseases (n, %) 21 (47) 154 (35) 0.12
Allergic rhinosinusitis (n, %) 28 (64) 218 (51) 0.13
Asthma (n, %) 14 (31) 96 (22) 0.16
Food allergy (n, %) 14 (33) 93 (24) 0.19
History of steroid treatment (n, %) 39 (85) 310 (67) 0.01
aCharacterized by inability to pass an adult upper endoscope.
bp values for significant difference in distribution of proportions and p value for difference in mean age and median symptom length.
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Table 2
Endoscopic and histological findings in patients with narrow-caliber and regular-caliber 
esophagus
Narrow-calibera (n = 46) Regular-caliber (n = 467) P valueb
Endoscopic findings (n, %)
Rings 40 (87) 188 (41) <0.01
Linear Furrows 31 (67) 214 (46) <0.01
White Plaques 19 (41) 119 (26) 0.02
Decreased Vascularity 15 (33) 100 (22) 0.09
Crêpe-paper mucosa 6 (13) 17 (4) <0.01
Strictures 33 (72) 60 (13) <0.01
History of dilation (n, %) 46 (100) 123 (26) <0.01
Number of dilations (median, IQR) 3.0 (1-6) 1.0 (1-2) <0.01
aCharacterized by inability to pass an adult upper endoscope.
bP values for significant difference in distribution of proportions and P value for difference in median number of dilations.
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Table 3
Response to steroida treatment in patients with narrow-caliber and regular-caliber 
esophagus
Narrow-caliberb (n = 39) Regular-caliber (n = 310) P valuec
Symptom response to steroids (n, %) 14 (56) 175 (85) <0.01
EGD response to steroids (n, %) 17 (52) 146 (76) <0.01
Histologic response to steroids (n, %) 11 (33) 119 (63) <0.01
Maximum eosinophil count before steroids (median, IQR) eos/hpf 77.5 (33-100) 60.0 (37-100) 0.38
Maximum eosinophils after steroids (median, IQR) eos/hpf 45 (3-90) 3 (0-34) <0.01
a
Defined as any topical swallowed corticosteroid formulation.
bCharacterized by inability to pass an adult upper endoscope.
cP values for significant difference in distribution of proportions and P value for difference in maximum eosinophil count.
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Table 4
Association between presence of narrow-caliber esophagus and symptomatic, endoscopic, 
and histologica response to steroidb treatment
Unadjusted odds ratio (95% CI) Adjustedc odds ratio (95% CI)
Symptom response to steroids (n, %) 0.22 (0.09-0.53) 0.28 (0.08-0.96)
EGD response to steroids (n, %) 0.33 (0.15-0.70) 0.31 (0.10-0.90)
Histologic response to steroids (n, %) 0.29 (0.13-0.64) 0.27 (0.09-0.74)
a
Defined as <15 eosinophils/hpf.
b
Defined as any topical swallowed corticosteroid formulation.
cAdjusted for symptom duration, history of dilation, and age at biopsy.
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Table 5
Demographic and clinical characteristics of patients with extreme narrow-caliber and 
patients with strictures
Narrow-calibera (n = 46) Stricturesb (n = 60) P valuec
Age at biopsy (mean years, SD) 33.4 (13.1) 36.7 (15.5) 0.26
Male (n, %) 32 (70) 47 (78) 0.30
Whites (n, %) 42 (93) 52 (87) 0.37
Symptoms (n, %)
Dysphagia 45 (98) 56 (97) 0.70
Food impaction 24 (53) 23 (46) 0.48
Chest pain 5 (11) 5 (10) 0.83
Heartburn 11 (24) 16 (31) 0.45
Abdominal pain 2 (4) 3 (6) 0.75
Nausea 1 (2) 3 (6) 0.36
Vomiting 7 (16) 4 (8) 0.25
Failure to thrive 1 (2) 1 (2) 0.94
Symptom length before diagnosis (median years, IQR) 11.0 (5-15) 8 (3-19) 0.97
Atopic diseases (n, %) 21 (47) 18 (37) 0.33
Allergic rhinosinusitis (n, %) 28 (64) 23 (51) 0.23
Asthma (n, %) 14 (31) 13 (27) 0.62
Food allergy (n, %) 14 (33) 9 (22) 0.28
History of steroid treatment (n, %) 39 (85) 40 (67) 0.03
History of dilation (n, %) 46 (100) 49 (82) <0.01
aCharacterized by requiring a neonatal endoscope to traverse the esophagus.
b
Patients with strictures and without a narrow-caliber esophagus.
cP values for significant difference in distribution of proportions and P value for difference in mean age and median symptom length.
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Table 6
Response to steroida treatment in patients with strictures without a narrow-caliber 
esophagus and narrow-caliber esophagus
Narrow-caliberb (n = 46) Stricturesc (n = 60) P valued
Symptom response to steroids (n, %) 14 (56) 24 (89) <0.01
EGD response to steroids (n, %) 17 (52) 23 (88) <0.01
Histologic response to steroids (n, %) 11 (33) 17 (68) <0.01
Maximum eosinophil count before steroids (median, IQR) eos/hpf 78 (33-100) 73 (36-111) 0.81
Maximum eosinophils after steroids (median, IQR) eos/hpf 45 (3-90) 2 (0-16) <0.01
a
Defined as any topical swallowed corticosteroid formulation.
bCharacterized by inability to pass an adult upper endoscope.
c
Patients with strictures and without a narrow-caliber esophagus.
dP values for significant difference in distribution of proportions and P value for difference in maximum eosinophil count.
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